

1 **Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the**
2 **acceleration of lymphatic filariasis elimination in Kenya: Programmatic**
3 **implementation and results of the first impact surveillance**

4 Sammy M. Njenga^{1*}, Henry Kanyi¹, Collins Okoyo^{1,2}, Edward Githinji¹, Cassian Mwatele¹,
5 Hadley S. Matendechero³, Wyckliff P. Omondi³, Patrick N. Gitahi³, Chrispin Owaga⁴, Joyce
6 K. Onsongo⁵, Katherine Gass⁶

7

8 ¹Eastern and Southern Africa Centre of International Parasite Control, Kenya Medical
9 Research Institute, Nairobi, Kenya

10 ²Department of Epidemiology, Statistics and Informatics, Kenya Medical Research Institute,
11 Nairobi, Kenya

12 ³Vector-borne and Neglected Tropical Diseases Unit, Ministry of Health, Nairobi, Kenya

13 ⁴Evidence Action, Nairobi, Kenya

14 ⁵WHO Country Office, World Health Organization, Nairobi, Kenya

15 ⁶NTD Support Center, Task Force for Global Health, Atlanta, USA

16

17 * Corresponding Author

18 Email: snjenga@kemri.go.ke (SMN)

19

20 **Abstract**

21 The World Health Organization (WHO) endorsed the use of triple-drug mass drug
22 administration (MDA) regimen with ivermectin, diethylcarbamazine (DEC) and albendazole
23 (commonly abbreviated as IDA) to accelerate the elimination of lymphatic filariasis (LF) as a

24 public health problem in settings where onchocerciasis is not co-endemic. The National
25 Programme for Elimination of LF (NPELF) in Kenya was among the first adopters of the IDA-
26 MDA and two annual rounds were provided in 2018 and 2019 to the residents of Lamu
27 County and Jomvu sub-County in the coast region. There is a need to determine efficient
28 sampling strategies, indicators, and the appropriate population groups that could be used for
29 the monitoring and evaluation of LF programs using IDA-MDA for the elimination of the
30 disease as a public health problem. Two cross-sectional surveys were conducted at baseline
31 in 2018 before IDA-MDA and an impact assessment 17 months after the second round of
32 IDA-MDA. The reported epidemiological treatment coverage was at least 80% in all
33 implementation units during each round of IDA-MDA. Blood samples were tested for
34 circulating filarial antigens using commercial Filariasis Test Strips (FTS) and any individual
35 that was found to be positive was tested again at night for the presence of microfilariae in
36 finger prick blood smears using microscopy. The overall prevalence of LF infection was
37 relatively low at the baseline survey with Jomvu having 1.39% (95% CI: 0.91, 2.11) and
38 Lamu having 0.48% (95% CI: 0.21, 1.13). Significant reductions in LF prevalence were
39 observed during the impact assessment after two annual rounds of treatment. The overall
40 relative risk reduction (%) in LF prevalence following the two rounds of MDA with IDA was
41 significant in both Jomvu (52.45%, $Z = -2.46$, $P < 0.02$) and Lamu (52.71%, $Z = -1.97$, $P <$
42 0.05). Heterogeneity, however, was observed in the LF prevalence reduction between
43 random and purposive clusters, as well as between adult and child populations. The results
44 of the endline impact survey offered strong evidence that it was safe to stop the IDA-MDA in
45 the two EUs because transmission appears to have been interrupted. It is also important to
46 implement a post-treatment surveillance system which would enable efficient detection of
47 any recrudescence of LF infection transmission at a sub-evaluation unit level. Our findings
48 show that IDA-MDA may be considered for acceleration of LF elimination in other settings
49 where onchocerciasis is not co-endemic.

50 **Author summary**

51 Preventive chemotherapy with antifilarial drugs is currently the mainstay public health
52 intervention recommended for the elimination of lymphatic filariasis in endemic countries.
53 Two-drug regimen mass drug administration of albendazole plus either diethylcarbamazine
54 or ivermectin has been used widely in most countries since the launch of the Global
55 Programme to Eliminate Lymphatic Filariasis by the World Health Organization in 2000.
56 Safety and efficacy clinical studies conducted in Papua New Guinea have shown that co-
57 administration of three antifilarial drugs namely, ivermectin, diethylcarbamazine and
58 albendazole is superior than the two-drug regimen diethylcarbamazine and albendazole in
59 clearance of microfilariae from the bloodstream. Consequently, the triple-drug regimen was
60 endorsed for accelerating efforts to eliminate lymphatic filariasis as a public health problem
61 in areas where onchocerciasis is not co-endemic. The aim of this study was to assess the
62 feasibility of delivering mass treatment with the triple-drug regimen under programmatic
63 conditions. An operational research study was conducted to determine the optimal sampling
64 strategies, indicator (or set of indicators), and study populations for monitoring and
65 evaluation of lymphatic filariasis programs using the triple-drug regimen mass drug
66 administration. Two rounds of mass treatment with the triple-drug regimen were given to the
67 residents of Lamu County (comprising of Lamu East and Lamu West sub-counties) and
68 Jomvu sub-County (in Mombasa) in November 2018 and November 2019. The programme
69 epidemiological treatment coverage was at least 80% in each implementation unit during the
70 two treatment rounds. The preventive treatment resulted in significant reductions in the
71 prevalence of the disease with the number of positive cases being fewer than the threshold
72 recommended for areas where transmission is likely to be no longer sustainable.

73 **Introduction**

74 Lymphatic filariasis (LF), commonly known as elephantiasis, is a mosquito-borne
75 neglected tropical disease (NTD) caused by infection with the filarial nematode species
76 *Wuchereria bancrofti*, *Brugia malayi* or *B. timori* (1). The parasites are transmitted from

77 person to person by mosquitoes belonging to the genera *Culex*, *Anopheles*, *Mansonia* and
78 *Aedes*. Clinically, LF infection may be asymptomatic, but can also lead to acute and chronic
79 conditions, including lymphoedema (swelling of the tissues, primarily the legs) and hydrocele
80 (scrotal swelling). In 2000, the World Health Organization (WHO) launched the Global
81 Programme to Eliminate LF (GPELF) as a public health problem (2, 3). The GPELF has two
82 principal aims: (i) to interrupt LF transmission, and (ii) to manage morbidity and prevent
83 disability. To interrupt transmission of LF infection, the GPELF recommends annual
84 community-wide mass drug administration (MDA) of two-drug treatment regimen
85 (albendazole plus either ivermectin or diethylcarbamazine) to entire at-risk populations for 4
86 to 6 years at adequate levels of coverage. Modelling studies have estimated adequate
87 treatment coverage to be at least 65% of the total population in endemic areas (4, 5).

88 It is estimated that the GPELF resulted in substantial health and economic benefits
89 during the first 15 years (6). Overall, an estimated 36 million clinical cases and on average
90 175 million disability-adjusted life years (DALYs) were potentially averted during the period.
91 In economic terms, an estimated US\$100.5 million was potentially saved through medical
92 expenses, potential income loss, and costs to the health system.

93 Approximately 4 million people are at-risk for LF in Kenya, residing in six counties (23
94 sub-counties) of the coastal region, including Kilifi, Kwale, Lamu, Tana River, Mombasa, and
95 Taita Taveta. Kenya started an MDA programme with diethylcarbamazine (DEC) plus
96 albendazole in 2002 in the then Kilifi district and expanded to include Malindi and Kwale
97 districts in 2003. The geographic coverage was progressively expanded over the years to
98 include other districts in the coastal region except Mombasa city and its peri-urban areas.
99 However, the programme faced financial and operational challenges which led to MDA being
100 missed in some years and complete cessation after the 2011 MDA. Nonetheless, the non-
101 consecutive rounds of MDA led to considerable reduction in the prevalence of LF (7). The
102 MDA programme was restarted in 2015 and baseline population surveys confirmed that LF

103 prevalence was still greater than the 2% antigenemia threshold in several areas (8), thus
104 justifying the resumption of MDA campaigns.

105 Findings of clinical trials suggest that co-administration of the three drugs used to
106 treat LF (ivermectin, DEC, and albendazole - IDA) results in improved efficacy for clearing
107 *W. bancrofti* microfilariae (Mf), which is the transmissible stage of the filarial parasite, and
108 sterilization of adult filarial worms (9-11). In 2017, following a thorough review process of
109 data from safety and efficacy trials of the triple-drug regimen, the WHO recommended it as
110 an alternative MDA regimen for the acceleration of LF elimination (12). The guidelines
111 recommend the use of annual IDA in specific settings where onchocerciasis is not co-
112 endemic with LF including places where MDA has not yet started, fewer than 4 effective
113 MDA rounds have been administered, and where MDA results have been sub-optimal.
114 Following the WHO's formal approval and release of the alternative treatment guidelines,
115 Merck and the MECTIZAN[®] Donation Program (MDP) promised to work with the WHO,
116 national LF programs and other stakeholders to develop a mechanism to enable for the
117 deployment of any required additional donation (13). The announcement was a major
118 enabler for the adoption of the IDA regimen by endemic countries. Computer simulation
119 modelling suggests that the triple-drug regimen has the potential to dramatically accelerate
120 the elimination of LF if epidemiological treatment coverage is high and systematic non-
121 compliance is low (14).

122 Sentinel site surveys conducted throughout the coastal region in 2015 and 2016
123 identified Lamu East and Jomvu sub-counties as the sites with the highest prevalence of LF
124 (6.3% and 6.7% antigenemia, respectively) (8). Lamu county had received one round of
125 MDA in 2011 and additional two rounds in 2016 and 2017 using the two-drug regimen of
126 DEC and albendazole, and all the three MDA rounds had achieved effective coverage (i.e.,
127 $\geq 65\%$ of the total population was treated). Jomvu, however, had received two rounds of
128 MDA (in 2016 and 2017), but none exceeded the 65% treatment coverage threshold. Due to
129 the historically high prevalence of LF, the intermittent history of MDA and the sub-optimal

130 coverage, both Lamu county and Jomvu sub-county were selected to receive two annual
131 rounds of the triple-drug (IDA) preventive chemotherapy in order to accelerate LF
132 elimination. For successful implementation of MDA with IDA, WHO recommends
133 epidemiological treatment coverage of 80% and above, with 100% geographic coverage.

134 In evaluation units where two-drug MDA is given for 5 to 6 consecutive years and the
135 LF infection reduced to the recommended thresholds, the WHO recommends post-MDA
136 surveillance using transmission assessment surveys (TAS) among six- and seven-year-old
137 children (15). Critical cut-off values of numbers of circulating filarial antigen (CFA) positive
138 children are employed to determine whether transmission has been interrupted in the
139 evaluation units. While the TAS has proven to be an effective tool for basing MDA stopping
140 decisions under the standard two-drug regimens, it is unclear whether the target age group
141 and epidemiologic target (<2% antigenemia in areas with *W. bancrofti* infections) are
142 appropriate when IDA is used. Because IDA will result in an accelerated interruption of
143 transmission, an operational research study was done with the goal of establishing the target
144 populations, infection indicators, sampling strategies, and thresholds required to determine
145 when it is safe to stop MDA with IDA. In this paper, we report on the NPELF experience
146 delivering MDA with IDA in three implementation units in coastal Kenya. The study also
147 presents an analysis of the baseline and endline survey results from the operational
148 research study in two evaluation units following IDA implementation.

149

150 **Methods and study design**

151 **Study sites**

152 Two rounds of MDA with IDA were provided in November 2018 and November 2019
153 in three sub-counties on the Kenyan coast: two (Lamu East and Lamu West sub-counties) in
154 Lamu County and the other one (Jomvu sub-County) in Mombasa County. For the IDA
155 impact survey, Lamu County, which is comprised of a mainland and several islands and is
156 situated on north coast of Kenya near the border with Somalia, was considered as a single

157 Evaluation Unit (EU), due to its relatively low population. Jomvu sub-county formed the
158 second EU and encompasses a mixture of urban, peri-urban and a few rural areas. In both
159 EUs, the village served as the primary sampling unit (PSU) for the cluster sampling survey.

160 **Approach for MDA implementation**

161 Due to the critical importance of achieving high treatment coverage for MDA with
162 IDA, and the fact that the new triple-drug regimen required ingestion of more medicines than
163 the two-drug regimen (DEC and albendazole) used previously, various strategies were
164 implemented to bolster compliance and treatment coverage.

165 **Robust partnerships**

166 Local and international collaborations played a pivotal role in supporting the
167 program's execution. Partners such as Evidence Action, The Task Force for Global Health's
168 NTD Support Center, and the END Fund provided essential logistical, technical, and
169 financial support, thus contributing to the successful implementation of the program.
170 Evidence Action with support from the END Fund provided fiscal management and technical
171 assistance in the following areas: design and procurement of training materials including
172 those for advocacy, communication, and social mobilization (ACSM); logistics for drug
173 delivery; and budget management for county and sub-county training and sensitization. The
174 Kenya Medical Research Institute (KEMRI) with support from the NTD Support Center at
175 The Task Force for Global Health provided technical support for baseline surveys and follow-
176 up monitoring and evaluation (M&E). The Africa Institute of Health and Development (AIHD)
177 conducted formative research that influenced the review of ACSM materials and identified
178 specific population segments with lower program engagement that may benefit from
179 intensified mobilization. The description and results of the formative research will be reported
180 elsewhere.

181 **Adverse event management and pharmacovigilance tools**

182 Since clinical trials in Papua New Guinea had shown that MDA with IDA is superior in
183 parasite clearance, it was anticipated that there would be a heightened risk of adverse

184 events (AEs) which necessitated deployment of a robust pharmacovigilance framework.
185 Collaboration with Kenya's Pharmacy and Poisons Board (PPB) enabled the implementation
186 of comprehensive pharmacovigilance tools, including reporting forms. Medications to help
187 manage any AEs were procured and stocked, including cetirizine, paracetamol, and
188 prednisolone. The AE forms were part of the training manuals and community drug
189 distributors' (CDD) handbooks. To ensure that any community members' questions or
190 concerns about the drugs could be promptly addressed, the PPB gave their hotline numbers
191 to be used in case of the occurrence of serious adverse events (SAEs).

192 **Enhanced Community Engagement and Supervision**

193 Community health extension workers (CHEWs) played a pivotal role in engaging
194 communities through community meetings (commonly known as *baraza*) and supportive
195 supervision of the CDDs. The number of individuals targeted by each CDD was reduced
196 from 500 to 300, which allowed the CDD to spend more time in each household to answer
197 any questions, ensure accurate dosing and recording, and to directly observe the medicines
198 being swallowed. There was also closer supervision of CDDs, with one CHEW overseeing
199 ten CDDs, compared to 20 in the conventional two-drug MDA. Additionally, the duration of
200 the IDA-MDA campaigns lasted for six days, compared to five days in the conventional two-
201 drug MDA. All of these adjustments allowed the implementers to pay closer attention to
202 detail and assured community members of the safety and importance of taking the
203 medicines. Frequent echo-messaging was done with the CHEWs and chiefs reminding them
204 of the key LF and IDA-MDA information they needed to share with their constituents through
205 intense social mobilization.

206 **Innovative Delivery Strategies to reach program targets**

207 Special attention was given to areas that were historically challenging to access,
208 addressing the needs of systematic non-compliers. To maximize treatment coverage, the
209 program ventured beyond conventional strategies by directly administering MDA in industrial
210 areas and utilizing boats to reach remote islands. Fixed posts, temporary fixed posts, and

211 door-to-door distribution were among the treatment strategies employed. For the first time,
212 MDA was taken directly to factories in the industrial areas. This was an innovative way to
213 capture populations typically missed by MDA campaigns by meeting them where they
214 usually spend their days. Boats were also hired to reach the far-off islands that were
215 previously missed and branded as hard-to-reach areas.

216 **Effective CDD selection and health care workers training**

217 The selection of CDDs was a crucial determinant of program success. By recruiting
218 retired health professionals and individuals from private chemists, the program leveraged the
219 community's trust in these respected persons. Similar strategies were employed in gated
220 communities to enhance acceptance among diverse populations. These individuals are well
221 known to the community members as health professionals which encouraged uptake. In the
222 gated communities, prior appointments had to be made and members of these communities
223 were selected as CDDs to boost the trust of these 'upper class' individuals. Training of
224 CHEWs and other sub-county implementation teams was centralized and conducted
225 simultaneously for all the cadres in order to ensure that accurate information was provided,
226 and to minimize loss of information about the new triple therapy down the cascade.

227 **Involvement of champions**

228 The involvement of individuals directly affected by the disease as LF champions
229 during the MDA campaigns added a human element to the program. The narratives of the
230 LF champions were shared during program launches, encouraging community members to
231 actively participate in the IDA-MDA. During the launch of the campaign in Lamu, for
232 example, these individuals openly explained how their lives had been negatively affected by
233 LF, and dispelled the commonly held belief that hydrocele surgery would particularly make
234 the men infertile. The support of the top leadership in the implementation areas was also
235 critical for ensuring the success of the campaigns. In Lamu, for example, the Governor
236 graced the IDA-MDA campaign launch and openly swallowed the medicines (a total of 9
237 pills) which sent a strong message that the intervention is indeed safe.

238 **Survey design and sampling strategy**

239 Cross-sectional epidemiological and entomological baseline surveys and follow-up
240 IDA-MDA impact assessment were conducted in 30 and 5-10 random and purposive clusters
241 (villages), respectively. This report, however, focuses on the population-based
242 epidemiological survey arm for which the baseline survey was conducted in October-
243 November, 2018 and the follow-up impact assessment in April – May, 2021. The village
244 served as the primary sampling unit (PSU) in this study. A two-armed sampling strategy was
245 employed to select random and purposive PSUs as described below.

246 **Random sampling**

247 All PSUs in the EU were listed in geographical order along with their respective
248 population sizes from which 30 PSU (aka ‘clusters’) were selected using probability
249 proportionate to estimated size (PPES) sampling. An Excel tool was created to aid study
250 investigators in the selection of the clusters.

251 **Purposive sampling**

252 During the baseline survey, 5 clusters in each EU were selected to become the
253 purposive PSUs, based on suspicion of high transmission of LF. The selection of the 5
254 purposive clusters was done in consultation with the NPELF officers and local health
255 workers. During the impact assessment, however, up to 10 clusters were purposively
256 selected. To maximize the chances of selecting sites with ongoing transmission during the
257 impact assessment, the purposive clusters were chosen to be the 5 villages with the highest
258 CFA prevalence in children 5-9 years of age in the baseline survey and up to 5 additional
259 villages that had the greatest proportion of positive mosquito pools (if these sites were
260 different from the initial 5 selected villages based on CFA prevalence in children). If there
261 were fewer than 5 sites with CFA positive children, the CFA prevalence in adults was used
262 to determine greatest risk of LF transmission for the purposive site selection.

263 **Human sample size**

264 Since the mosquito vectors responsible for LF transmission in coastal Kenya belong
265 to *Culex* and *Anopheles* species (16), the sample size was powered to enable the detection
266 of a 2% CFA threshold for each of two age groups: (1) children aged 5-9 years old and other
267 community members aged >10 years during the baseline survey, and (2) children aged 5-9
268 years-old and other community members aged ≥ 18 years during the endline impact
269 assessment. The sample size of the 5-9 years-old children that was required for the random
270 cluster survey in each area was selected to be similar to the sample sizes used for the
271 WHO-recommended TAS survey (15). The target population and sample size were adjusted
272 for the endline impact survey based on WHO's interim guidance to use a 1% Mf threshold in
273 adults (≥ 18 years) with 95% confidence to assess the impact of IDA (17). S1 and S2 Tables
274 show the sample sizes that were required during each survey time point. In each survey, the
275 individuals were enrolled to participate if they had lived in the areas for at least 12 months.

276 **Blood sampling and testing for LF infection**

277 Written informed consent was obtained from all adults and parents or guardians of
278 children below 18 years old. Ethical approval of the study protocols and informed consent
279 documents was obtained from the Kenya Medical Research Institute Scientific and Ethics
280 Review Unit (KEMRI/SERU Protocol No. 3721 and 4099). Blood sampling was done in two
281 human populations: children (age 5-9 years) and older persons (age ≥ 10 and ≥ 18 years in
282 baseline and endline surveys, respectively). The blood specimens were tested for CFA in the
283 field using the Filariasis Test Strip (FTS) as recommended by the manufacturer (Alere,
284 Scarborough, Maine, USA). Briefly, 75 μ l of finger prick blood was collected from each
285 consenting participant into one of the capillary containers provided by the manufacturer and
286 placed on the test pad. The test results were read and recorded at exactly 10 minutes.
287 Additional blood specimen was collected from the same prick site for preparation of a dried-
288 blood spot (DBS) specimen to be used for serological assays later. Any individuals found to
289 be positive by the FTS test were followed up for a second blood specimen collection during

290 hours of peak Mf circulation (9 pm – midnight). Approximately 60µl of the nighttime blood
291 sample was used for thick blood smear microscopy and another 60µl for DBS preparation.
292 The nighttime DBS was preserved for later detection of parasite DNA using a quantitative
293 real-time polymerase chain reaction (qPCR) method.

294

295 **Data management and analysis**

296 In the field, data were collected on smartphones and regularly uploaded to an
297 electronic database using the open-source software Secure Data Kit (SDK). Data sets were
298 stored on a SQL secure server. Field staff were trained on how to use the tools for data
299 collection in the field. The investigators had access to view and download the data sets in
300 real time using a secure password-protected website.

301 A primary goal of the data analysis was to determine whether the decrease in LF
302 prevalence among children aged 5-9 years is consistent with TAS guidelines for stopping
303 MDA, as compared to any decrease in FTS and Mf prevalence among adults. To address
304 this primary study objective, the prevalence of CFA was assessed within each evaluation
305 unit by each age group (5-9 years and ≥18 years) and the upper 1-sided 95% confidence
306 limits calculated, assuming a hypergeometric distribution and taking into account survey
307 design.

308 Infection prevalence was calculated and the 95% confidence intervals (CIs)
309 determined using a binomial regression model, taking into account clustering by villages. To
310 assess impact of IDA, the relative risk reductions (RRR) in CFA prevalence from baseline to
311 endline impact survey were calculated using multivariable mixed effects models with random
312 intercepts for the clusters and implementation units and P-values obtained using Wald test.
313 The relative risk reduction was calculated using the following formula,

$$314 \text{ RRR} = \left[\frac{\text{Baseline prevalence} - \text{Endline prevalence}}{\text{Baseline prevalence}} \right] \times 100\%.$$

315 All statistical analyses were carried out using STATA version 16.1 (STATA
 316 Corporation, College Station, TX, USA). Graphs were developed using the ggplot package
 317 implemented in R software. Village locations were mapped using ArcGIS Desktop version
 318 10.2.2 software (Environmental Systems Research Institute Inc., Redlands, CA, USA).

319

320 Results

321 In Kenya, the MDA implementation unit is the sub-county (equivalent of district in
 322 most other African countries). Although Lamu County was considered as a single EU for the
 323 operational research study, the two sub-counties in this area were considered separate
 324 implementation units (IUs) during MDA with IDA. Table 1 shows the epidemiological
 325 treatment coverage (reported coverage) with IDA-MDA in the three IUs in 2018 and 2019.
 326 An independent treatment coverage evaluation survey undertaken soon after the IDA-MDA
 327 to validate the epidemiological treatment confirmed that high treatment coverage was indeed
 328 achieved (Table 1).

329 **Table 1. Coverage of two rounds of mass drug administration (MDA) with triple-drug**
 330 **therapy (ivermectin, diethylcarbamazine and albendazole - IDA) in Lamu and Jomvu**
 331 **implementation units, 2018 and 2019.**

	2018			2019		
IU	No. treated/Target population	Reported coverage (%)	Coverage evaluation survey (%)	No. treated/Target population	Reported coverage (%)	Coverage evaluation survey (%)
Lamu East	19,428/24,179	80	ND	19,892/24,905	80	ND
Lamu	86,006/104,532	82	82	97,897/107,668	91	78

West						
Jomvu	147,496/149,579	99	90	171,172/154,067	111	ND

332 ND: Not done

333 Overall, a total of 6,559 individuals were enrolled for the baseline survey out of whom 3,095
 334 and 3,464 were from Lamu and Jomvu, respectively (Table 2). Out of 10,694 individuals
 335 enrolled during the IDA-MDA endline impact survey, 5,235 and 5,459 were from Lamu and
 336 Jomvu, respectively.

337

338 **Table 2. Baseline and IDA-MDA endline impact survey characteristics in each**
 339 **evaluation unit (EU).**

Survey timepoint	EU	Cluster type	Age category	No. sampled	Median age (range; SD)	Travel outside IU in the past 1 year
Baseline	Jomvu	Random	Child	1,469	7 (5-9; SD=1.48)	0
			Adults*	1,470	27 (10-91; SD=14.70)	306
		Purposive	Child	238	8 (5-9; SD=1.47)	0
			Adults*	287	27 (10-75; SD=13.22)	66
		All sites	Child	1,707	7 (5-9; SD=1.48)	0
			Adults*	1,757	27 (10-91; SD=14.47)	372
	Lamu	Random	Child	1,329	7 (5-9; SD=1.40)	0
			Adults*	1,340	28 (10-101; SD=14.47)	464

					SD=17.97)	
		Purposive	Child	198	7 (5-9; SD=1.36)	0
			Adults*	228	26 (10-85; SD=18.18)	82
		All sites	Child	1,527	7 (5-9; SD=1.40)	0
			Adults*	1,568	27 (10-101; SD=18.00)	546
Endline impact survey	Jomvu	Random	Child	1,331	8 (5-9; SD=1.54)	0
			Adults*	2,807	30 (18-95; SD=12.71)	581
		Purposive	Child	430	8 (5-9; SD=1.53)	0
			Adults*	891	30 (18-81; SD=11.93)	258
		All sites	Child	1,761	8 (5-9; SD=1.54)	0
			Adults*	3,698	30 (18-95; SD=12.53)	839
	Lamu	Random	Child	1,413	8 (5-9; SD=1.39)	0
			Adults*	3,100	32 (18-102; SD=15.11)	875
		Purposive	Child	234	8 (5-9; SD=1.45)	0
			Adults*	488	35 (18-95; SD=15.99)	171
		All sites	Child	1,647	8 (5-9; SD=1.40)	0
			Adults*	3,588	32 (18-102; SD=15.25)	1,046

340 *Adult population consisted of individuals aged 10 years and above (baseline) and persons
341 aged 18 years and above (endline); the child population consisted of 5-9 years old children
342 both during baseline survey and impact assessment.

343 Table 3 summarizes the prevalence of LF infection in the two EUs, while comparing
344 children and adult populations and the random and purposive clusters. In general, the overall
345 prevalence of LF infection by FTS in both types of clusters was relatively low at the baseline
346 survey, with Jomvu having 1.39% (95%CI: 0.91,2.11) and Lamu having 0.48% (95%CI: 0.21,
347 1.13). Of 15 FTS positive individuals identified during the baseline survey in Lamu, 3 were
348 children between the ages of 5 and 9 years. In contrast, of the 48 positive cases identified
349 during the baseline survey in Jomvu, 11 were children aged 5-9 years. Of the 63 FTS
350 positive cases, one individual aged between 40 and 50 years in Jomvu was found to have
351 three (3) Mf in the night blood sample.

352

353 **Table 3. LF infection prevalence during baseline and endline surveys, and relative reduction (RR %) stratified by cluster type.**

	Lamu			Jomvu		
Cluster type	Random	Purposive	All sites	Random	Purposive	All sites
Baseline survey (2018)						
No. of clusters	30	5	35	30	5	35
Overall: No. FTS positive/ No. tested	9/2669	6/426	15/3095	40/2939	8/525	48/3464
Overall: Prevalence % (95% CI)	0.34% (0.18, 0.64)	1.41% (0.20, 10.16)	0.48% (0.21, 1.13)	1.36% (0.85, 2.19)	1.52% (0.57, 4.11)	1.39% (0.91, 2.11)
Children: No. FTS positive/ No. tested (Prevalence %); 95% CI	1/1329	2/198	3/1527	7/1469	4/238	11/1707

Children: Prevalence % (95% CI)	0.08 (0.01, 0.53)	1.01 (0.12, 8.45)	0.20 (0.05, 0.85)	0.48 (0.17, 1.37)	1.68 (0.56, 5.04)	0.64 (0.30, 1.40)
Adults: No. FTS positive/ No. tested	8/1340	4/228	12/1568	33/1470	4/287	37/1757
Adults: Prevalence % (95% CI)	0.60 (0.30, 1.17)	1.75 (0.27, 11.27)	0.77 (0.36, 1.63)	2.24 (1.45, 3.48)	1.39 (0.52, 3.71)	2.11 (1.41, 3.15)
Baseline impact survey (2021)						
No. of clusters	31	5	36	30	9	39
Overall: No. FTS positive/ No. tested	3/4514	9/722	12/5236	34/4143	2/1321	36/5464
Overall: Prevalence % (95% CI)	0.07 (0.02, 0.20)	1.25 (0.23, 6.63)	0.23 (0.06, 0.86)	0.82 (0.51, 1.31)	0.15 (0.04, 0.55)	0.66 (0.41, 1.05)

Children: No. FTS positive/ No. tested (Prevalence %); 95% CI	0/1413	0/234	0/1647	3/1331	0/430	3/1761
Children: Prevalence % (95% CI)	0	0	0	0.23 (0.08, 0.68)	0	0.17 (0.06, 0.52)
Adults: No. FTS positive/ No. tested (Prevalence %); 95% CI	3/3100	9/488	12/3588	31/2807	2/891	33/3698
Adults: Prevalence % (95% CI)	0.10 (0.03, 0.29)	1.84 (0.35, 9.86)	0.33 (0.09, 1.26)	1.10 (0.69, 1.77)	0.22 (0.06, 0.81)	0.89 (0.56, 1.42)
Relative risk reduction (%) in LF prevalence between baseline and endline surveys [RRR, Z-statistic, p-value]						
Overall	RRR=80.29%, Z=-2.56, p=0.011*	RRR=11.50%, Z=0.55, p=0.582	RRR=52.71%, Z=1.97, p=0.049*	RRR=39.70%, Z=1.57, p=0.116	RRR=90.06%, Z=3.64, p<0.001*	RRR=52.45%, Z=-2.46, p=0.014*
Children	RRR=100.00%, Z=7.20, p<0.001*	RRR=100.00%, Z=4.24, p<0.001*	RRR=100.00%, Z=8.33, p<0.001*	RRR=52.70%, Z=0.91, p=0.365	RRR=100.00%, Z=7.29, p<0.001*	RRR=73.56%, Z=-1.80, p=0.072

adults	RRR=83.79%, Z=-2.94, p=0.003*	Incr=5.12%, Z=0.41, p=0.679	RRR=56.30%, Z=-1.63, p=0.063	RRR=50.80%, Z=-2.36, p=0.018*	RRR=83.89%, Z=-2.56, p=0.010*	RRR=57.62%, Z=-3.03, p=0.002*
---------------	-------------------------------	-----------------------------	------------------------------	-------------------------------	-------------------------------	-------------------------------

354 *Indicates a significant relative risk reduction in prevalence between baseline and endline

355 CI: confidence interval; RRR: Relative risk reduction in prevalence; Incr: Increase in prevalence

356 While there was an apparent reduction in the overall prevalence of LF infection
357 following the administration of two rounds of MDA with IDA, the reduction was not consistent
358 across the two EUs and study populations. Despite Lamu having very low numbers of LF
359 positive cases in the baseline survey, there was observed statistically significant decrease in
360 prevalence between the baseline and endline surveys, RRR = 52.71% (Wald test: $Z = -1.97$,
361 $p = 0.049$). This significant decline in Lamu was largely attributed to the random clusters,
362 RRR = 80.29% (Wald test: $Z = -2.56$, $p = 0.011$). In Jomvu, where LF prevalence was
363 relatively higher at baseline survey, the overall reduction in LF prevalence was significant in
364 the purposive villages, RRR = 90.06% (Wald test: $Z = -3.64$, $p < 0.001$), but not in the
365 random sites, RRR = 39.70% (Wald test: $Z = -1.97$, $p = 0.116$). The reduction in LF
366 prevalence among the adult population after the two rounds of IDA-MDA in Jomvu was
367 significant in both random, RRR = 50.80% (Wald test: $Z = -2.36$, $p = 0.018$) and purposive,
368 RRR = 83.89% (Wald test: $Z = -2.56$, $p = 0.010$) clusters. Restricting the analysis to children
369 in Jomvu, the reduction was only significant among the purposive villages, RRR = 100.00%
370 (Wald test: $Z = -7.29$, $p < 0.001$) but not in the randomly selected villages, RRR = 52.70%
371 (Wald test: $Z = -0.91$, $p = 0.365$).

372 In general, there was a greater number of LF positive clusters in Jomvu compared
373 with Lamu during both surveys (Table 4, and Figs 1 and 2). A total of 11 out of 35 clusters in
374 Jomvu had LF prevalence of 2% or above during the baseline survey, compared with 4 out
375 of 39 clusters during the endline impact survey. In contrast, Lamu had 2 out of 35 clusters
376 with LF prevalence of 2% or above during the baseline survey and 1 out of 36 clusters
377 during the endline impact survey.

378

379 **Table 4. LF positivity among the study clusters (villages) in the two EUs during the**
 380 **baseline and endline surveys stratified by point prevalence categories.**

LF prevalence category (%)	Number of clusters	
	Lamu	Jomvu
Baseline prevalence (%)	N = 35	N = 35
0	26	16
0.1 – 0.9	3	4
1.0 – 1.9	4	4
2.0 – 4.9	1	9
≥ 5	1	2
Impact surveillance prevalence (%)	N = 36	N = 39
0	31	19
0.1 – 0.9	4	13
1.0 – 1.9	0	3
2.0 – 4.9	0	4
≥ 5	1	0

381

382

383

384 **Fig 1. LF infection rates by FTS test at baseline and endline (after 2 rounds of IDA-**
 385 **MDA) among study clusters in the two EUs. The inset map of Kenya shows the**
 386 **location of the two study areas.**

387

388

389

390 **Fig 2. Village-level prevalence of LF infection by FTS test at baseline and endline**
 391 **(after 2 rounds of IDA-MDA), stratified by evaluation unit. Points represent point**
 392 **prevalence (%) with 95% confidence interval (CI) error bars.**

393

394 At the endline survey, none of the 5–9-year-old children tested for LF infection were
 395 positive in Lamu, while 3 were found to be positive in Jomvu. Compared with the WHO
 396 recommended transmission survey (TAS), the FTS positive child cases observed in both
 397 EUs were below the threshold (Table 7).

398

399 **Table 7.** Endline IDA-MDA impact survey results in 5-9 years children, compared with
 400 transmission assessment survey (TAS) thresholds

	Results during endline impact surveillance		WHO recommended TAS thresholds	
	Jomvu	Lamu	Jomvu	Lamu
Number of clusters	39	36	30	30
Sample size	1761	1647	1392	1532
Cases/ critical cut-off	3	0	16	18

401 The age group for the endline survey was children 5-9 years compared to the 6-7 years
 402 recommended for TAS, which increased the risk for failing TAS.

403 Discussion

404 Compliance to the triple-drug regimen MDA in Lamu county and Jomvu sub-county
405 was dramatically high due to excellent social mobilization by the National Programme for
406 Elimination of LF (NPELF) and implementing partners. The various integrated strategies that
407 were employed during MDA with IDA in the two areas in coastal region of Kenya showcased
408 how a comprehensive approach can be employed to achieve high treatment coverage.
409 Through partnerships, tailored communication, robust adverse event management,
410 community engagement, innovative delivery mechanisms, effective CDD selection, and the
411 involvement of LF champions, the program demonstrated the potential for achieving high
412 treatment coverage. The treatment data demonstrated that the 80% treatment coverage
413 target recommended by WHO could be realized. Indeed, the NPELF and partners were so
414 successful in their social mobilization efforts that people from neighbouring sub-counties not
415 meriting IDA-MDA travelled to Jomvu to receive the drugs (as is evident from the MDA
416 coverage exceeding 100% in Jomvu). The results imply that NTD endemic communities will
417 support the introduction of innovative treatments when the benefits of this change are clearly
418 explained to them.

419 The results of the endline IDA-MDA impact survey offer strong evidence that it is safe
420 to stop the IDA regimen in the two EUs because transmission appears to have been
421 interrupted. Computer simulation modelling (14) predicts that in settings with a low baseline
422 prevalence of LF (5%), the triple-drug regimen reduces the number of rounds of MDA
423 required to reach the target prevalence by one or two rounds, compared with the two-drug
424 regimen.

425 The detection of one Mf positive individual among the FTS positive cases in Jomvu
426 indicates the presence of active LF transmission, albeit at relatively very low level and likely
427 highly focal. In *W. bancrofti* endemic settings, demonstrating that the population prevalence
428 of FTS positive cases is below a defined threshold in a transmission assessment survey
429 (TAS) is an indication that LF is no longer a public health problem in the evaluation unit (15).

430 However, measuring CFA alone may not be an adequate way to for monitoring and
431 evaluation of LF elimination programs using IDA-MDA (18). Indeed, evidence from initial IDA
432 safety and efficacy clinical studies showed persistence of CFA for five years after a single
433 round of IDA-MDA even with sustained clearance of Mf (10, 19). Thus, the development of
434 new and more sensitive diagnostics tools, particularly for use during post-MDA with IDA
435 surveillance, is urgently required to detect recrudescence. The use of entomological
436 sampling and molecular detection of filarial DNA in mosquito vectors, known as molecular
437 xenomonitoring is also considered a surveillance tool for LF that may have particular utility in
438 low prevalence settings, and thus could supplement the standard diagnostics (20-22).
439 However, although molecular xenomonitoring can also be used to detect the presence of the
440 parasite in mosquito vectors and is a sensitive indicator of microfilaraemia, it is not a direct
441 measure of infectivity or current rates of parasite transmission (15). Another challenge with
442 molecular xenomonitoring is that it is not yet known how to interpret a signal of infection in
443 mosquitoes (e.g., what is the threshold for action?) and the approach is laborious, expensive
444 and requires diagnostic techniques that aren't readily available to many NTD programs.

445 There is growing appreciation that basing MDA stopping decisions on the mean EU
446 prevalence is not enough. As LF transmission approaches interruption, the remaining
447 infection becomes increasingly focal and it is important to critically examine cluster-level
448 results when determining whether a stop treatment decision is appropriate. The cluster data
449 presented in Figs 1 and 2, as well as Table 4, present reassurance that post-IDA-MDA, there
450 do not appear to be any remaining foci of infection that merit programmatic action.
451 Nonetheless, the fact that 4 clusters in Jomvu and 1 in Lamu had a cluster-level FTS
452 prevalence above 2% is an indication that the NPELF should remain vigilant of these sites
453 during post-treatment surveillance to ensure that the lingering signal is a sign of waning
454 infection and not recrudescence.

455 Since the implementation of MDA with IDA requires a substantial increase in
456 programmatic resource expenditures, it may be necessary to restrict IDA-MDA to areas

457 where the extra effort is necessary to drive transmission below the breakpoint.
458 Consequently, it will be necessary to critically review the results of the transmission
459 assessment surveys after the two rounds of MDA with IDA to determine if the EU meets the
460 stopping criteria and can begin post-treatment surveillance. Intensive research surveys using
461 serological approaches in American Samoa revealed residual hotspots with ongoing LF
462 transmission several years after MDA was stopped (23, 24). Therefore, conducting an active
463 post-treatment surveillance may be appropriate to determine if and when there is
464 recrudescence.

465 Monitoring and evaluation (M&E) and surveillance are critical activities of any NTD
466 control or elimination programme. The interim guidance for IDA-MDA impact surveillance is
467 to test adults aged 20 years and above for circulating filarial antigenemia in 30 randomly
468 selected clusters. The finding that there was significant reduction of LF infection prevalence
469 among the adult population after the two rounds of annual IDA-MDA in the random clusters
470 corroborates the proposal to conduct post-treatment surveillance among adults in randomly
471 selected villages, and to employ microfilaraemia as an indicator for the presence of current
472 infection. In an effort to make post-treatment surveillance of NTDs cost-effective in low-
473 resource settings, a model-based geostatistics approach that would result in a survey design
474 that requires sampling fewer clusters and a smaller total sample size while still achieving the
475 same predictive qualities as conventional MDA impact surveillance approaches has been
476 proposed (25, 26). It will therefore be important to consider conducting a follow-on
477 operational research study as part of the second IDA-MDA impact surveillance in the two
478 settings in order to provide additional evidence on the application of model-based
479 geostatistics for its application in LF endemic countries where MDA with IDA is being
480 considered.

481 This study has several limitations worth highlighting. The coast region of Kenya may
482 be considered a low prevalence setting due to the impact of several rounds of the two-drug
483 regimen MDA with DEC and albendazole and the widespread bednet usage. Lamu had

484 received one round of MDA in 2011 (66% epidemiological treatment coverage) before the
485 NPELF stopped mass treatments. Thereafter, Lamu received 3 rounds of consecutive MDA
486 rounds in 2015, 2016 and 2017 and all were above the 65% epidemiological treatment
487 threshold. Lamu was included primarily due to the historical persistence of LF infection in
488 Lamu East particularly in Ndau island. With regard to Jomvu, two rounds of MDA with DEC
489 and albendazole had been given in 2016 and 2017 but both were below the recommended
490 65% threshold. The missed opportunity to assess the impact of IDA-MDA on other diseases,
491 particularly transmitted helminthiasis (STH), scabies, and head lice may be considered a
492 study limitation. Ivermectin is known to act strongly against a wide variety of insects,
493 nematodes, and acarine parasites, including lice and scabies (27, 28). A study to assess the
494 impact of IDA-MDA for LF and STH control in Timor-Leste reported significant reduction in
495 the prevalence of scabies, impetigo, and STH (*Trichuris trichiura* and *Ascaris lumbricoides*)
496 among schoolchildren (29).

497 A noteworthy strength of the study, however, is that the design of the cross-sectional
498 surveys provided for the inclusion of both children and adult populations in both the baseline
499 and endline impact assessment. The random sampling in Jomvu at baseline revealed
500 pockets of ongoing transmission hitherto unknown to the NPELF. The results of the study
501 also indicate that purposive sites have a critical role in LF surveillance, particularly in
502 identifying areas with highest risk of LF transmission (putative hot spots). In Lamu for
503 example, Ndau island is historically known to be an area with relatively high LF transmission
504 (30), which was also confirmed during a previous survey (8). Laboratory serologic and
505 molecular (PCR) results are still forthcoming and when reported will shine even greater light
506 on the impact of MDA with IDA – both spatially and across the age groups.

507 In conclusion, this study shows that the two rounds of IDA-MDA reduced LF infection
508 below the recommended thresholds in the two EUs. The study also demonstrated that
509 programmatic delivery of MDA with IDA is a feasible and efficient strategy for endemic
510 countries looking to accelerate their LF elimination programs as they move towards post-

511 treatment surveillance. The operational research study enabled baseline and endline
512 collection of data that will be useful to guide global policy on monitoring and evaluation of LF
513 programs that implement IDA-MDA. With a remaining, albeit very low, signal of CFA in the
514 community, it is important to implement a post-treatment surveillance system which would
515 enable efficient detection of any recrudescence of LF infection transmission at a sub-
516 evaluation unit level.

517

518 **Supporting information captions**

519 **S1 Table.** Sample size determination during the baseline survey conducted in 2018.

520 **S2 Table.** Sample size determination during the impact surveillance conducted in 2021.

521 **Acknowledgements**

522 We express our gratitude to the county departments of health in Lamu and Mombasa
523 for their excellent cooperation and support of the MDA with IDA and the associated
524 operational research study. We would also like to thank the fieldwork teams for assistance
525 with data collection. The local residents and operational research participants are
526 acknowledged for their voluntary participation and commitment in this study. The partners,
527 including Evidence Action, Africa Institute for Health and Development, Division of Vector-
528 Borne and Neglected Tropical Diseases, Kenya Medical Research Institute, and the NTD
529 Support Centre provided excellent technical support. The study was generously funded by
530 the United States Agency for International Development (USAID) and Bill & Melinda Gates
531 Foundation (BMGF) through the Coalition for Operational Research on Neglected Tropical
532 Diseases (COR-NTD).

References

1. WHO. Global programme to eliminate lymphatic filariasis: progress report, 2021. Weekly Epidemiological Record. 2022;97(41):513–24

2. Ottesen EA. The global programme to eliminate lymphatic filariasis. *Trop Med Int Health*. 2000;5(9):591-4.
3. WHO. Global programme to eliminate lymphatic filariasis: progress report, 2019. *Weekly Epidemiological Record*. 2020;95(43):509-24.
4. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, et al. Mathematical modelling and the control of lymphatic filariasis. *Lancet Infect Dis*. 2004;4(4):223-34.
5. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. *J Infect Dis*. 2003;188(9):1371-81.
6. Turner HC, Bettis AA, Chu BK, McFarland DA, Hooper PJ, Ottesen EA, et al. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014). *Infect Dis Poverty*. 2016;5(1):54.
7. Njenga SM, Mwandawiro CS, Wamae CN, Mukoko DA, Omar AA, Shimada M, et al. Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control. *Parasit Vectors*. 2011;4:90.
8. Njenga SM, Kanyi HM, Mutungi FM, Okoyo C, Matendechero HS, Pullan RL, et al. Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya. *Parasit Vectors*. 2017;10(1):99.
9. Fischer PU, King CL, Jacobson JA, Weil GJ. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. *PLoS Negl Trop Dis*. 2017;11(1):e0005163.
10. King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, et al. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. *N Engl J Med*. 2018;379(19):1801-10.
11. Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. *Clin Infect Dis*. 2016;62(3):334-41.

12. WHO. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. World Health Organization, Geneva. 2017.
13. Merck. Merck Commemorates 30 Years of MECTIZAN® Donation Program Progress: MECTIZAN® Donation Program; 2017 [Available from: <https://www.merck.com/news/merck-commemorates-30-years-of-mectizan-donation-program-progress/>].
14. Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. *Lancet Infect Dis.* 2017;17(4):451-8.
15. WHO. Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. World Health Organization, Geneva. 2011.
16. Njenga SM, Kanyi HM, Mwatele CM, Mukoko DA, Bockarie MJ, Kelly-Hope LA. Integrated survey of helminthic neglected tropical diseases and comparison of two mosquito sampling methods for lymphatic filariasis molecular xenomonitoring in the River Galana area, Kilifi County, coastal Kenya. *PLoS One.* 2022;17(12):e0278655.
17. COR-NTD. IDA Technical Meeting Report, Seattle, WA, USA. Decatur, GA, USA: Task Force for Global Health, Neglected Tropical Diseases Support Center, Coalition for Operational Research on Neglected Tropical Diseases; October 2022.
18. Won KY, Gass K, Biamonte M, Dagne DA, Ducker C, Hanna C, et al. Diagnostics to support elimination of lymphatic filariasis-Development of two target product profiles. *PLoS Negl Trop Dis.* 2021;15(11):e0009968.
19. King CL, Weil GJ, Kazura JW. Single-Dose Triple-Drug Therapy for *Wuchereria bancrofti* - 5-Year Follow-up. *N Engl J Med.* 2020;382(20):1956-7.
20. Pryce J, Reimer LJ. Evaluating the Diagnostic Test Accuracy of Molecular Xenomonitoring Methods for Characterizing Community Burden of Lymphatic Filariasis. *Clin Infect Dis.* 2021;72(Suppl 3):S203-S9.

21. Riches N, Badia-Rius X, Mzilahowa T, Kelly-Hope LA. A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. *PLoS Negl Trop Dis*. 2020;14(5):e0008289.
22. Schmaedick MA, Koppel AL, Pilotte N, Torres M, Williams SA, Dobson SL, et al. Molecular xenomonitoring using mosquitoes to map lymphatic filariasis after mass drug administration in American Samoa. *PLoS Negl Trop Dis*. 2014;8(8):e3087.
23. Lau CL, Sheridan S, Ryan S, Roineau M, Andreosso A, Fuimaono S, et al. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. *PLoS Negl Trop Dis*. 2017;11(9):e0005914.
24. Sheel M, Sheridan S, Gass K, Won K, Fuimaono S, Kirk M, et al. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016. *PLoS Negl Trop Dis*. 2018;12(7):e0006583.
25. Fronterre C, Amoah B, Giorgi E, Stanton MC, Diggle PJ. Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. *J Infect Dis*. 2020;221(Suppl 5):S554-S60.
26. Johnson O, Fronterre C, Amoah B, Montresor A, Giorgi E, Midzi N, et al. Model-Based Geostatistical Methods Enable Efficient Design and Analysis of Prevalence Surveys for Soil-Transmitted Helminth Infection and Other Neglected Tropical Diseases. *Clin Infect Dis*. 2021;72(Suppl 3):S172-S9.
27. Fox LM. Ivermectin: uses and impact 20 years on. *Curr Opin Infect Dis*. 2006;19(6):588-93.
28. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. *N Engl J Med*. 1995;333(1):26-30.
29. Le B, Monteiro MAA, Amaral S, Wand H, Matthews A, Hii SF, et al. The impact of ivermectin, diethylcarbamazine citrate, and albendazole mass drug administration on the prevalence of scabies and soil-transmitted helminths in school-aged children in three municipalities in Timor-Leste: a before-after assessment. *Lancet Glob Health*. 2023;11(6):e924-e32.

30. Wijers DJ, Kaleli N. Bancroftian filariasis in Kenya. V. Mass treatment given by members of the local community. *Ann Trop Med Parasitol*. 1984;78(4):383-94.

533

534 **S1 Table. Sample size determination during the baseline survey conducted in 2018.**

Survey Timepoint	Survey Area	Estimated Population	Sample size for random cluster survey of children aged 5-9 years	Sample size for random cluster survey of adults*	Sample size for purposively selected sites of children aged 5-9 years	Sample size for purposively selected sites of adults*
Baseline	Lamu	144,000	1380	1710	200 (40 per site x 5 sites)	200 (40 per site x 5 sites)
	Jomvu	140,000	1380	1710	200 (40 per site x 5 sites)	200 (40 per site x 5 sites)
Endline	Lamu	144,000	1380 (average of 46 kids per site)	3150 (an average of 105 adults per site)	50 per site	100 per site
	Jomvu	140,000	1380 (average of 46 kids per site)	3150 (an average of 105 adults per site)	50 per site	100 per site

535 *During baseline adults were considered as participants aged 10 years, during endline adults

536 were considered as participants aged 18 years

537

538 **S2 Table. Sample size determination during the impact surveillance conducted in**
 539 **2021.**

540

Survey Area	Estimated Population	Sample size for random cluster survey of children aged 5-9 years	Sample size for random cluster survey of adults 18+ years old	Sample size for purposively selected sites of children aged 5-9 years	Sample size for purposively selected sites of adults 18+ years old
Lamu	144,000	1380 (average of 46 kids per site)	3150 (an average of 105 adults per site)	50 per site (in up to 5 sites*)	100 per site (in up to 5 sites*)
Jomvu	140,000	1380 (average of 46 kids per site)	3150 (an average of 105 adults per site)	50 per site (in up to 9 sites*)	100 per site (in up to 9 sites*)

541

542 *The exact number of clusters that were purposively selected was dependent on the number
 543 of high-risk villages; any 'high risk' villages not included in the random sample formed the
 544 purposively selected clusters.

Baseline: Jomvu

Baseline: Lamu


Cluster prevalence (%)

- 0%
- 0.1-0.9%
- 1.0-1.9%
- 2.0-4.9%
- $\geq 5.0\%$

Water body
County boundary


Endline: Jomvu

Endline: Lamu



0 1.25 2.5 5 Km

A) Jomvu



B) Lamu

